The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Pulmonary Hypertension Drug Market Research Report 2025
Synopsis
Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.
Global Chronic Pulmonary Hypertension Drug market is projected to reach US$ 9038.2 million in 2029, increasing from US$ 6312 million in 2022, with the CAGR of 5.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chronic Pulmonary Hypertension Drug market research.
The chronic pulmonary hypertension drug market is driven by the increasing prevalence of pulmonary hypertension and the growing demand for effective treatment options. Chronic pulmonary hypertension is a progressive and life-threatening condition characterized by high blood pressure in the pulmonary arteries, leading to heart and lung complications. The rise in risk factors such as obesity, cardiovascular diseases, and respiratory disorders contributes to market growth. The development of novel drugs, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, has significantly improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the complexity of managing the disease, potential side effects of medications, and the need for personalized treatment approaches. Additionally, the high cost of specialized therapies and the limited understanding of the disease's underlying mechanisms can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective chronic pulmonary hypertension drugs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Chronic Pulmonary Hypertension Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer
Attgeno
Cereno Scientific
Bial - Portela C S.A
Liquidia Technologies
Bellerophon Therapeutics
AbbVie Therapeutics
Insmed
Altavant Sciences
Lupin
Sun Pharmaceutical
Teva
Segment by Type
Oral
Intravenous/Subcutaneous
Inhalational
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Chronic Pulmonary Hypertension Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.
Global Chronic Pulmonary Hypertension Drug market is projected to reach US$ 9038.2 million in 2029, increasing from US$ 6312 million in 2022, with the CAGR of 5.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chronic Pulmonary Hypertension Drug market research.
The chronic pulmonary hypertension drug market is driven by the increasing prevalence of pulmonary hypertension and the growing demand for effective treatment options. Chronic pulmonary hypertension is a progressive and life-threatening condition characterized by high blood pressure in the pulmonary arteries, leading to heart and lung complications. The rise in risk factors such as obesity, cardiovascular diseases, and respiratory disorders contributes to market growth. The development of novel drugs, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, has significantly improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the complexity of managing the disease, potential side effects of medications, and the need for personalized treatment approaches. Additionally, the high cost of specialized therapies and the limited understanding of the disease's underlying mechanisms can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective chronic pulmonary hypertension drugs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Chronic Pulmonary Hypertension Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer
Attgeno
Cereno Scientific
Bial - Portela C S.A
Liquidia Technologies
Bellerophon Therapeutics
AbbVie Therapeutics
Insmed
Altavant Sciences
Lupin
Sun Pharmaceutical
Teva
Segment by Type
Oral
Intravenous/Subcutaneous
Inhalational
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Chronic Pulmonary Hypertension Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Intravenous/Subcutaneous
1.2.4 Inhalational
1.3 Market by Application
1.3.1 Global Chronic Pulmonary Hypertension Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Pulmonary Hypertension Drug Market Perspective (2018-2029)
2.2 Chronic Pulmonary Hypertension Drug Growth Trends by Region
2.2.1 Global Chronic Pulmonary Hypertension Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chronic Pulmonary Hypertension Drug Historic Market Size by Region (2018-2023)
2.2.3 Chronic Pulmonary Hypertension Drug Forecasted Market Size by Region (2024-2029)
2.3 Chronic Pulmonary Hypertension Drug Market Dynamics
2.3.1 Chronic Pulmonary Hypertension Drug Industry Trends
2.3.2 Chronic Pulmonary Hypertension Drug Market Drivers
2.3.3 Chronic Pulmonary Hypertension Drug Market Challenges
2.3.4 Chronic Pulmonary Hypertension Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Pulmonary Hypertension Drug Players by Revenue
3.1.1 Global Top Chronic Pulmonary Hypertension Drug Players by Revenue (2018-2023)
3.1.2 Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Players (2018-2023)
3.2 Global Chronic Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Pulmonary Hypertension Drug Revenue
3.4 Global Chronic Pulmonary Hypertension Drug Market Concentration Ratio
3.4.1 Global Chronic Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Pulmonary Hypertension Drug Revenue in 2022
3.5 Chronic Pulmonary Hypertension Drug Key Players Head office and Area Served
3.6 Key Players Chronic Pulmonary Hypertension Drug Product Solution and Service
3.7 Date of Enter into Chronic Pulmonary Hypertension Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Pulmonary Hypertension Drug Breakdown Data by Type
4.1 Global Chronic Pulmonary Hypertension Drug Historic Market Size by Type (2018-2023)
4.2 Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Type (2024-2029)
5 Chronic Pulmonary Hypertension Drug Breakdown Data by Application
5.1 Global Chronic Pulmonary Hypertension Drug Historic Market Size by Application (2018-2023)
5.2 Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
6.2 North America Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Chronic Pulmonary Hypertension Drug Market Size by Country (2018-2023)
6.4 North America Chronic Pulmonary Hypertension Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
7.2 Europe Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2018-2023)
7.4 Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
8.2 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
9.2 Latin America Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2018-2023)
9.4 Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
10.2 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Chronic Pulmonary Hypertension Drug Introduction
11.1.4 Bayer Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.1.5 Bayer Recent Development
11.2 Attgeno
11.2.1 Attgeno Company Detail
11.2.2 Attgeno Business Overview
11.2.3 Attgeno Chronic Pulmonary Hypertension Drug Introduction
11.2.4 Attgeno Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.2.5 Attgeno Recent Development
11.3 Cereno Scientific
11.3.1 Cereno Scientific Company Detail
11.3.2 Cereno Scientific Business Overview
11.3.3 Cereno Scientific Chronic Pulmonary Hypertension Drug Introduction
11.3.4 Cereno Scientific Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.3.5 Cereno Scientific Recent Development
11.4 Bial - Portela C S.A
11.4.1 Bial - Portela C S.A Company Detail
11.4.2 Bial - Portela C S.A Business Overview
11.4.3 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Introduction
11.4.4 Bial - Portela C S.A Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.4.5 Bial - Portela C S.A Recent Development
11.5 Liquidia Technologies
11.5.1 Liquidia Technologies Company Detail
11.5.2 Liquidia Technologies Business Overview
11.5.3 Liquidia Technologies Chronic Pulmonary Hypertension Drug Introduction
11.5.4 Liquidia Technologies Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.5.5 Liquidia Technologies Recent Development
11.6 Bellerophon Therapeutics
11.6.1 Bellerophon Therapeutics Company Detail
11.6.2 Bellerophon Therapeutics Business Overview
11.6.3 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Introduction
11.6.4 Bellerophon Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.6.5 Bellerophon Therapeutics Recent Development
11.7 AbbVie Therapeutics
11.7.1 AbbVie Therapeutics Company Detail
11.7.2 AbbVie Therapeutics Business Overview
11.7.3 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Introduction
11.7.4 AbbVie Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.7.5 AbbVie Therapeutics Recent Development
11.8 Insmed
11.8.1 Insmed Company Detail
11.8.2 Insmed Business Overview
11.8.3 Insmed Chronic Pulmonary Hypertension Drug Introduction
11.8.4 Insmed Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.8.5 Insmed Recent Development
11.9 Altavant Sciences
11.9.1 Altavant Sciences Company Detail
11.9.2 Altavant Sciences Business Overview
11.9.3 Altavant Sciences Chronic Pulmonary Hypertension Drug Introduction
11.9.4 Altavant Sciences Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.9.5 Altavant Sciences Recent Development
11.10 Lupin
11.10.1 Lupin Company Detail
11.10.2 Lupin Business Overview
11.10.3 Lupin Chronic Pulmonary Hypertension Drug Introduction
11.10.4 Lupin Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.10.5 Lupin Recent Development
11.11 Sun Pharmaceutical
11.11.1 Sun Pharmaceutical Company Detail
11.11.2 Sun Pharmaceutical Business Overview
11.11.3 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Introduction
11.11.4 Sun Pharmaceutical Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.11.5 Sun Pharmaceutical Recent Development
11.12 Teva
11.12.1 Teva Company Detail
11.12.2 Teva Business Overview
11.12.3 Teva Chronic Pulmonary Hypertension Drug Introduction
11.12.4 Teva Revenue in Chronic Pulmonary Hypertension Drug Business (2018-2023)
11.12.5 Teva Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
